Taxane induced neuropathy in patients affected by breast cancer: Literature review

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 1, 2015, Pages 34-45

  De Iuliis, Francesca ^a   Taglieri, Ludovica ^a   Salerno, Gerardo ^a   Lanza, Rosina ^a   Scarpa, Susanna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anticonvulsants; Antidepressants; Antioxidants; Breast cancer; Neurotoxicity; Pharmacogenomics; Taxane; Vitamins

Indexed keywords

ACETYLCARNITINE; ALPHA TOCOPHEROL; AMIFOSTINE; AMITRIPTYLINE; ANTIOXIDANT; ASCORBIC ACID; BACLOFEN; CARBAMAZEPINE; CARBOPLATIN; DULOXETINE; ERYTHROPOIETIN; ETHOXYQUIN; GABAPENTIN; GLUTAMINE; GLUTATHIONE; GOSHAJINKIGAN; HERBACEOUS AGENT; KETAMINE; LAMOTRIGINE; NERVE GROWTH FACTOR; NEURITE PROMOTING FACTOR; OXALIPLATIN; PACLITAXEL; PLACEBO; PREGABALIN; SOMATOMEDIN; TAXANE DERIVATIVE; THIOCTIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; NEUROPROTECTIVE AGENT; TAXOID;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; ELECTROSTIMULATION THERAPY; HUMAN; MEASUREMENT; MEDICAL ASSESSMENT; NEUROLOGICAL THERAPEUTIC DEVICE; NEUROPATHY; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TAXANE INDUCED NEUROPATHY; BREAST NEOPLASMS; FEMALE; NEUROTOXICITY SYNDROMES; PHARMACOECONOMICS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; BREAST NEOPLASMS; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; TAXOIDS;

EID: 84942194400     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.04.011     Document Type: Review

References (97)

1. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983.
2. Argyriou A.A., Koltzenburg M., Polychronopoulos P., Papapetropoulos S., Kalofonos H.P. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008, 66:218-228.
3. Carlson K., Ocean A.J. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer 2011, 11:73-81.
4. Hershman D.L., Weimer L.H., Wang A., et al. Association between patient reported outcomes and quantitative sensory tests for measuring longterm neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011, 125:767-774.
5. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:1663-1671.
6. Swain S.M., Arezzo J.C. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008, 6:455-467.
7. Chaudhry V., Chaudhry M., Crawford T.O., Simmons-O'Brien E., Griffin J.W. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003, 60:337-340.
8. Dougherty P.M., Cata J.P., Cordella J.V., Burton A., Weng H.R. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004, 109:132-142.
9. Pignata S., De Placido S., Biamonte R., et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the multicenter Italian trial in ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006, 6:5.
10. Loprinzi C.L., Reeves B.N., Dakhil S.R., et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011, 29:1472-1478.
11. Hegarty A., Portenoy R.K. Pharmacotherapy of neuropathic pain. Semin Neurol 1994, 14:213-224.
12. Zheng H., Xiao W.H., Bennett G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011, 232:154-161.
13. Peters C.M., Jimenez-Andrade J.M., Jonas B.M., Sevcik M.A., Koewler N.J., Ghilardi J.R. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 2007, 203:42-54.
14. Cata J.P., Weng H.R., Lee B.N., Reuben J.M., Dougherty P.M. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006, 72:151-169.
15. Dougherty P., Cata J.P., Cordella J.V., Burton A., Weng H.R. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004, 109:132-142.
16. Gribkoff V.K. The role of voltage-gated calcium channels in pain and nociception. Semin Cell Dev Biol 2006, 17:555-564.
17. Kawakami K., Chiba T., Katagiri N., Saduka M., Abe K., Utsunomiya I. Paclitaxel increases high voltage-dependent calcium channel current in dorsal root ganglion neurons of the rat. J Pharmacol Sci 2012, 120:187-195.
18. Ustinova E.E., Shurin G.V., Gutkin D.W., Shurin M.R. The role of TLR4 in the paclitaxel effects on neuronal growth in vitro. PLoS ONE 2013, 8(2):e56886. 10.1371/journal.pone.0056886.
19. McClure R., Massari P. TLR-dependent human mucosal epithelial cell responses to microbial pathogens. Front Immunol 2014, 5:386.
20. Kawasaki K., Akashi S., Shimazu R., Yoshida T., Miyake K., Nishijima M. Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol. J Endotoxin Res 2001, 7:232-236.
21. Barajon I., Serrano G., Arnaboldi F., et al. Toll-like receptors 3, 4 and 7 are espresse in the enteric nervous system and dorsal root ganglia. J Histochem Cytochem 2009, 57:1013-1023.
22. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980, 77:1561-1565.
23. La Pointe N.E., Morfini G., Brady S.T., Feinstein S.C., Wilson L., Jordan M.A. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 2013, 37:231-239.
24. Peters C.M., Jimenez-Andrade J.M., Kuskowski M.A., Ghilardi J.R., Mantyh P.W. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007, 1168:46-59.
25. Weng H.R., Aravindan N., Cata J.P., Chen J.H., Shaw A.D., Dougherty P.M. Spinal glial glutamate transporters downregulate in rats with taxol-induced hyperalgesia. Neurosci Lett 2005, 386:18-22.
26. Miyano K., Tang H.B., Nakamura Y., Morioka N., Inoue A., Nakata Y. Paclitaxel and vinorelbine, evoked the release of substance P from cultured rat dorsal root ganglion cells through different PKC isoform-sensitive ion channels. Neuropharmacology 2009, 57:25-32.
27. Wozniak K.M., Nomoto K., Lapidus R.G., et al. Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel and ixabepilone in mice. Cancer Res 2011, 71:3952-3962.
28. Boyette-Davis J.A., Cata J.P., Driver L.C., et al. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. Cancer Chemother Pharmacol 2013, 71:619-626.
29. Kennedy W.R., Wendelschafer-Crabb G., Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology 1996, 47:1042-1048.
30. Petersen K.L., Rice F.L., Farhadi M., Reda H., Rowbotham M.C. Natural history of cutaneous innervation following herpes zoster. Pain 2010, 150:75-82.
31. Boyette-Davis J., Xin W., Zhang H., Dougherty P.M. Intraepidermal nerve fiber loss corresponds to the development of Taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain 2011, 152:308-313.
32. Siau C., Xiao W., Bennett G.J. Paclitaxel- and vincristine evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 2006, 201:507-514.
33. Cavaletti G., Frigeni B., Lanzani F., et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 2010, 46:479-494.
34. Griffith K.A., Merkies I.S., Hill E.E., Cornblath D.R. Measures of chemotherapy-induced peripheral neuropathy. J Pheripher Nerv Syst 2010, 15:314-325.
35. Postma T.J., Aaronson N.K., Heimans J.J., et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005, 41:1135-1139.
36. Smith E.M., Beck S.L., Cohen J. The total neuropathy score (TNS): a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 2008, 35:96-102.
37. Smith E.M., Cohen J.A., Pett M.A., Beck S.L. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums. Cancer Nurs 2010, 33:173-183.
38. ®) for chemotherapy induced peripheral neuropathy. J Pain Symptom Manage 2010, 40:883-891.
39. Wolf S., Barton D., Kottschade L., Grothey A., Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008, 44:1507-1515.
40. Pachman D.R., Barton D.L., Watson J.C., Loprinzi C.L. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 2011, 90:377-387.
41. Hershman D.L., Lacchetti C., Dworkin R.H., et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014, 32:1941-1967.
42. Beijers A.J., Jongen J.L., Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med 2012, 70:18-25.
43. Ziegler D., Reljanovic M., Mehnert H., Gries F.A. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999, 107:421-430.
44. Kottschade L.A., Sloan J.A., Mazurczak M.A., et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer 2011, 19:1769-1777.
45. Argyriou A.A., Chroni E., Koutras A., et al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage 2006, 32:237-244.
46. Loprinzi C.L., Dakhil S.R., Fehrenbacher L., et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity, N08CB (Alliance). J. Clin Oncol 2014, 32:997-1005.
47. Kelly G.S. l-Carnitine: therapeutic applications of a conditionally-essential amino acid. Altern Med Rev 1998, 3:345-360.
48. Seifried H.E., Anderson D.E., Sorkin B.C., Costello R.B. Free radicals: the pros and cons of antioxidants. Executive summary report. J Nutr 2004, 134:3143-3163.
49. Pisano C., Pratesi G., Laccabue D., et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-l-carnitine. Clin Cancer Res 2003, 9:5756-5767.
50. De Grandis D., Minardi C. Acetyl-l-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D 2002, 3:223-231.
51. Xiao W.H., Zheng H., Bennett G.J. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 2012, 203:194-206.
52. Bianchi G., Vitali G., Caraceni A., Ravaglia S., Capri G., Cundari S. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-l-carnitine. Eur J Cancer 2005, 41:1746-1750.
53. Hershman D.L., Unger J.M., Crew K.D., et al. Randomized double-blind placebo-controlled trial of acetyl-l-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013, 31:2627-2633.
54. Cascinu S., Cordella L., Del Ferro E., Fronzoni M., Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995, 13:26-32.
55. Mir O., Alexandre J., Tran A., et al. Relationship between GSTP Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 2009, 20:736-740.
56. Leal A.D., Qin R., Atherton P.J., et al. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 2014, 120:1890-1897.
57. Vahdat L., Papadopoulos K., Lange D., et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001, 7:1192-1197.
58. Stubblefield M.D., Vahdat L.T., Balmaceda C.M., Troxel A.B., Hesdorffer C.S., Gooch C.L. Glutamine as a neuroprotective agent in high-dose paclitaxel- induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 2005, 17:271-276.
59. Wang W.S., Lin J.K., Lin T.C., et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007, 12:312-319.
60. Strasser F., Demmer R., Böhme C., et al. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. Oncologist 2008, 13:337-346.
61. Loven D., Levavi H., Sabach G., et al. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Eur J Cancer Care 2009, 18:78-83.
62. Rao R.D., Michalak J.C., Sloan J.A., et al. Efficacy of gabapentin in the management of chemotherapy induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007, 110:2110-2118.
63. Nguyen V.H., Lawrence H.J. Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol 2004, 22:1767-1769.
64. Saif M., Syrigos K., Kaley K., Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res 2010, 30:2927-2933.
65. Kautio A.L., Haanpää M., Leminen A., Kalso E., Kautiainen H., Saarto T. Amitriptyline in the prevention of chemo-induced neuropathic symptoms. Anticancer Res 2009, 29:2601-2606.
66. Barton D.L., Wos E.J., Qin R., et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2011, 19:833-841.
67. Smith E.M., Pang H., Cirrincione C., et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013, 309:1359-1367.
68. Otake A., Yoshino K., Ueda Y., et al. Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients. Anticancer Res 2015, 35:359-363.
69. Rao R.D., Flynn P.J., Sloan J.A., et al. Efficacy of lamotrigine in the management of chemotherapyinduced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 2008, 112:2802-2808.
70. Verstappen C.C., Postma T.J., Geldof A.A., Heimans J.J. Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation. Anticancer Res 2004, 24:2337-2341.
71. Moore D.H., Donnelly J., McGuire W.P., Almadrones L., Cella D.F., Herzog T.J. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:4207-4213.
72. Lorusso D., Ferrandina G., Greggi S., et al. Multicenter Italian Trials in Ovarian Cancer Investigators: phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003, 14:1086-1093.
73. Hilpert F., Stähle A., Tomé O., et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy-a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) ovarian cancer study group. Support Care Cancer 2005, 13:797-805.
74. Openshaw H., Beamon K., Synold T.W., et al. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 2004, 10:461-467.
75. De Vos F.Y., Bos A.M., Schaapveld M., et al. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol 2005, 97:60-67.
76. Zhu J., Chen W., Mi R., Zhou C., Reed N., Höke A. Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation. Ann Neurol 2013, 74:893-904.
77. Verheyen A., Peeraer E., Lambrechts D., et al. Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies. Neuroscience 2013, 244:77-89.
78. Apfel S.C., Arezzo J.C., Lipson L., Kessler J.A. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992, 31:76-80.
79. Hayakawa K., Itoh T., Niwa H., Mutoh T., Sobue G. NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: in vitro study of adult rat sympathetic ganglion explants. Brain Res 1998, 794:313-319.
80. Hayakawa K., Itoh T., Niwa H., et al. Nerve growth factor prevention of aged-rat sympathetic neuron injury by cisplatin, vincristine and taxol-in vitro explant study. Neurosci Lett 1999, 274:103-106.
81. Contreras P.C., Vaught J.L., Gruner J.A., Brosnan C., Steffler C., Arezzo J.C. Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice. Brain Res 1997, 774:20-26.
82. Boucher T.J., Okuse K., Bennett D.L., Munson J.B., Wood J.N., McMahon S.B. Potent analgesic effects of GDNF in neuropathic pain states. Science 2000, 290:124-127.
83. Kassem L.A., Yassin N.A. Role of erythropoeitin in prevention of chemotherapy-induced peripheral neuropathy. Pak J Biol Sci 2010, 13:577-587.
84. Cervellini I., Bello E., Frapolli R., et al. The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats. Neurotox Res 2010, 18:151-160.
85. Weber B., Largillier R., Ray-Coquard I., et al. A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial. Support Care Cancer 2013, 21:1947-1954.
86. Eckel F., Schmelz R., Adelsberger H., Erdmann J., Quasthoff S., Lersch C. Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study. Dtsch Med Wochenschr 2002, 127:78-82.
87. Kaku H., Kumagai S., Onoue H., et al. Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: a multicenter collaborative study. Exp Ther Med 2012, 3:60-65.
88. Green H., Soderkvist P., Rosenberg P., et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 2009, 104:130-137.
89. Leskela S., Jara C., Leandro-Garcia L.J., et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 2011, 11:121-129.
90. Bergmann T.K., Green H., Brasch-Andersen C., et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 2011, 67:693-700.
91. Sissung T.M., Mross K., Steinberg S.M., et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006, 42:2893-2896.
92. De Graan A.J., Elens L., Sprowl J.A., et al. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res 2013, 19:3316-3324.
93. Leandro-García L.J., Leskelä S., Jara C., et al. Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res 2012, 18:4441-4448.
94. McWhinney-Glass S., Winham S.J., Hertz D.L., et al. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Canc Res 2013, 19:5769-5776.
95. Sucheston L.E., Zhao H., Yao S., et al. Genetic predictors of taxane induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 2011, 130:993-1002.
96. Hershman D.L., Weimer L.H., Wang A., et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011, 125:767-774.
97. Gornstein E., Schwarz T.L. The paradox of paclitaxel neurotoxicity: mechanisms and unanswered questions. Neuropharmacology 2014, 76:175-183.